|Status: In progress|
Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
|Medicine name||dupilumab (Dupixent®)|
|Formulation||200 mg solution for injection, 300 mg solution for injection|
|BNF chapter||Respiratory system|
|Submission type||Licence extension for paediatric use|
|AWMSG meeting date||14/09/2022|
|Date of issue||TBC|